Literature DB >> 26072362

Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma.

Antonio Tejera-Vaquerizo1, Eduardo Nagore2, Susana Puig3, Caroline Robert4, Philippe Saiag5, Paula Martín-Cuevas6, Elena Gallego7, Enrique Herrera-Acosta8, José Aguilera9, Josep Malvehy10, Cristina Carrera11, Andrea Cavalcanti12, Ramón Rull13, Antonio Vilalta-Solsona14, Emilie Lannoy15, Celine Boutros16, Naima Benannoune17, Gorana Tomasic18, Philippe Aegerte19, Sergi Vidal-Sicart20, Josep Palou21, L Lúcia Alos22, Celia Requena23, Víctor Traves24, Ángel Pla25, Isidro Bolumar26, Virtudes Soriano27, Carlos Guillén28, Enrique Herrera-Ceballos29.   

Abstract

INTRODUCTION: In patients with primary cutaneous melanoma, there is generally a delay between excisional biopsy of the primary tumour and sentinel-node biopsy. The objective of this study is to analyse the prognostic implications of this delay. PATIENTS AND
METHOD: This was an observational, retrospective, cohort study in four tertiary referral hospitals. A total of 1963 patients were included. The factor of interest was the interval between the date of the excisional biopsy of the primary melanoma and the date of the sentinel-node biopsy (delay time) in the prognosis. The primary outcome was melanoma-specific survival and disease-free survival.
RESULTS: A delay time of 40 days or less (hazard ratio (HR), 1.7; confidence interval (CI), 1.2-2.5) increased Breslow thickness (Breslow ⩾ 2 mm, HR, > 3.7; CI, 1.4-10.7), ulceration (HR, 1.6; CI, 1.1-2.3), sentinel-node metastasis (HR, 2.9; CI, 1.9-4.2), and primary melanoma localised in the head or neck were independently associated with worse melanoma-specific survival (all P < 0.03). The stratified analysis showed that the effect of delay time was at the expense of the patients with a negative sentinel-node biopsy and without regression.
CONCLUSION: Early sentinel-node biopsy is associated with worse survival in patients with cutaneous melanoma.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Melanoma; Prognosis; Sentinel lymph node; Skin surgery; Waiting list

Mesh:

Year:  2015        PMID: 26072362      PMCID: PMC4768477          DOI: 10.1016/j.ejca.2015.05.023

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  29 in total

Review 1.  Inflammatory skin diseases, T cells, and immune surveillance.

Authors:  C Robert; T S Kupper
Journal:  N Engl J Med       Date:  1999-12-09       Impact factor: 91.245

Review 2.  Cross-presentation in viral immunity and self-tolerance.

Authors:  W R Heath; F R Carbone
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

Review 3.  Homing and cellular traffic in lymph nodes.

Authors:  Ulrich H von Andrian; Thorsten R Mempel
Journal:  Nat Rev Immunol       Date:  2003-11       Impact factor: 53.106

4.  Human Langerhans cells are immature in melanoma sentinel lymph nodes.

Authors:  Gianni Gerlini; Paola Di Gennaro; Giulia Mariotti; Carmelo Urso; Alberto Chiarugi; Roberto Caporale; Nicola Pimpinelli; Lorenzo Borgognoni
Journal:  Blood       Date:  2012-05-17       Impact factor: 22.113

5.  Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments.

Authors:  M Mazumdar; J R Glassman
Journal:  Stat Med       Date:  2000-01-15       Impact factor: 2.373

6.  Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study.

Authors:  F H Sim; W F Taylor; D J Pritchard; E H Soule
Journal:  Mayo Clin Proc       Date:  1986-09       Impact factor: 7.616

7.  Cytokine profiles of sentinel lymph nodes draining the primary melanoma.

Authors:  Stanley P L Leong; Miao Peng; Yuan-Ming Zhou; Julio E Vaquerano; John W C Chang
Journal:  Ann Surg Oncol       Date:  2002 Jan-Feb       Impact factor: 5.344

8.  The prognostic impact of the anatomical sites in the 'head and neck melanoma': scalp versus face and neck.

Authors:  Vincenzo de Giorgi; Susanna Rossari; Alessia Gori; Marta Grazzini; Imma Savarese; Emanuele Crocetti; Elisa Cervadoro; Daniela Massi
Journal:  Melanoma Res       Date:  2012-10       Impact factor: 3.599

9.  Is the identification of in-transit sentinel lymph nodes in malignant melanoma patients really necessary?

Authors:  Sergi Vidal-Sicart; Francesca Pons; Silvia Fuertes; Antonio Vilalta; Ramón Rull; Susana Puig; Josep M Palou; Marisa Ortega; Teresa Castel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-03       Impact factor: 9.236

10.  Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.

Authors:  Jeffrey D Wagner; Jaimie Ranieri; David Z Evdokimow; Theodore Logan; Tsu-Yi Chuang; Cynthia S Johnson; Sin-Ho Jung; Stacie Wenck; John J Coleman
Journal:  Plast Reconstr Surg       Date:  2003-08       Impact factor: 4.730

View more
  2 in total

1.  Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma.

Authors:  Daniel W Nelson; Stacey Stern; David E Elashoff; Robert Elashoff; John F Thompson; Nicola Mozzillo; Omgo E Nieweg; Harald J Hoekstra; Alistair J Cochran; Mark B Faries
Journal:  J Am Coll Surg       Date:  2017-06-28       Impact factor: 6.113

2.  Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19.

Authors:  M Arenbergerova; A Lallas; E Nagore; L Rudnicka; A M Forsea; M Pasek; F Meier; K Peris; J Olah; C Posch
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-04-13       Impact factor: 6.166

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.